Frontlight ResearchEarly access
Metastatic breast cancer trials in France
83 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 18 November 2026. Ask the study team whether a trial fits you.
- Phase 2Taking peopleClinical Trial Evaluating the Biological Activity of a New Drug Identified as Prifetrastat (PF-07248144), Combined With Fulvestrant for the Treatment of Patients With Hormone Receptor Positive (HR+) and HER2 Negative (HER2-) Breast Cancer Extended to Other Organs.
- Where
- Bordeaux, Lyon, Marseille, Nice Cedex 2, Paris, Rennes Cedex, Saint-Herblain Cedex, Toulouse Cedex 9, Villejuif
- Age
- 18 years and over
- People
- 51
- Run by
- UNICANCER
See details and how to joinNCT07340619 · EU 2025-521982-29-00 - Phase 2Taking peopleSafety and Efficacy of T-DXd vs. CDK4/6i-based ET as First-line Therapy of HR-positive and HER2-low/Ultralow Advanced Breast Cancer Patients Classified as Non-luminal Subtype
- Where
- Besançon, Caen Cedex 5, Dijon, Marseille, Paris, Pierre-Bénite, Saint-Herblain Cedex, Saint-Priest-en-Jarez
- Age
- 18 years and over
- People
- 200 worldwide
- Run by
- MedSIR
See details and how to joinNCT06486883 · EU 2024-512360-55-00 - Phase 2Taking peopleDecreasing Treatment for Metastatic HER2-Positive Breast Cancer With Undectable Cancer Levels in Blood Tests.
- Where
- Angers, Avignon Cedex 9, Bayonne, Beauvais, Bordeaux, Bourg En Bresse, Brest, Caen Cedex 5, Chambray-lès-Tours, Clermont Ferrand Cedex1, Clermont Ferrand Cedex 2, Compiègne, Dijon, Frejus, Limoges, Lyon, Marseille, MONTPELLIER, Nantes Cedex 2, Nice Cedex 2, Nîmes, Nimes Cedex 9, Osny, Paris, Paris Cedex 13, Paris Cedex 15, Plerin, Poitiers, Pontoise, Pringy Cedex, Reims, Rennes Cedex, Rouen, Saint-Cloud, Saint-Herblain Cedex, Strasbourg, Toulouse Cedex 9, Tours, Vandoeuvre Les Nancy_ Cedex, Villejuif
- Age
- 18 years and over
- People
- 170
- Run by
- UNICANCER
See details and how to joinNCT06450314 · EU 2023-509811-98-00 - Phase 3Taking peopleRising ctDNA to Tailor Endocrine Therapy Switch in Patients With ER+/HER2- Metastatic Breast Cancer.
- Where
- Avignon Cedex 9, Bordeaux, Bourg En Bresse, Caen Cedex 5, Clermont Ferrand Cedex1, Dijon, Epagny Metz-tessy, Le Mans Cedex 9, Lille, Limoges Cedex 1, Lorient, Lyon, Marseille, Nantes Cedex 2, Nice Cedex 2, Nimes Cedex 9, Paris, Pierre-Bénite, Plerin, Quimper Cedex, Reims, Rennes Cedex, Rouen Cedex, Saint-Cloud, Saint-Priest-en-Jarez, STRASBOURG, Toulouse Cedex 9, Tours Cedex 9, Vandoeuvre Les Nancy_ Cedex, Villejuif
- Age
- 18 years and over
- People
- 370
- Run by
- UNICANCER
See details and how to joinNCT07717450 · EU 2025-524213-84-00 - Phase 1/2Taking peopleFirst-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
- Where
- Bordeaux, Lyon, Marseille, Nice Cedex 2, Toulouse, Villejuif
- Age
- 18 years and over
- People
- 880 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT05768139 · EU 2023-504807-94-00 - Phase 1Taking peopleFirst-in-Human Study of OKI-219 Alone and in Combination with Other Therapies in Patients with Solid Tumors / Breast Cancer
- Where
- Dijon, Lille, Lyon, Nice Cedex 2, Pierre-Bénite, Villejuif
- Age
- 18 years and over
- People
- 145 worldwide
- Run by
- Onkure Inc.
See details and how to join2023-508435-31-00 - No phaseNot yet taking people in FranceCRYO-TOUCH: Cryoablation of the Primary Breast Tumor in Metastatic Breast Cancer
- Where
- Lyon
- Age
- 18 years and over
- People
- 42
- Run by
- Hospices Civils de Lyon
See details and how to joinNCT07676344 - Phase 2CompletedA Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TESARO-sponsored Niraparib Study
- Where
- Nantes Cedex 2, Nice Cedex 2
- Age
- 18 years and over
- People
- 37 worldwide
- Run by
- GlaxoSmithKline
See details and how to joinNCT04641247 · EU 2023-506618-29-00 - No phaseTaking peopleEvolution of the Therapeutic Care in Metastatic Breast Cancer From 2008
- Where
- Angers, Bordeaux, Caen, Clermont-Ferrand, Dijon, Lille, Lyon, Marseille, Montpellier, Nancy, Nantes, Nice, Paris, Reims, Rennes, Rouen, Saint-Cloud, Strasbourg, Toulouse, Villejuif
- Age
- 18 years and over
- People
- 42,000
- Run by
- UNICANCER
See details and how to joinNCT03275311 - No phaseTaking peopleComparison of Different Methods of CAPTure of Circulating Tumour Cells (CTC) in Patients With Metastatic Breast or Prostate Cancer
- Where
- Toulouse
- Age
- 18 years and over
- People
- 54
- Run by
- Institut Claudius Regaud
See details and how to joinNCT06904625 - Phase 1/2Taking peopleBeamion BCGC-1: A study to find a suitable dose of zongertinib used alone and in combination with other treatments to test whether it helps people with different types of HER2+ cancer that has spread
- Where
- Bordeaux, Caen Cedex 5, Dijon, Lyon, Marseille, Paris, Rennes Cedex, Saint-Herblain Cedex, Strasbourg, Toulouse, Villejuif
- Age
- 18 years and over
- People
- 181 worldwide
- Run by
- Boehringer Ingelheim International GmbH
See details and how to join2023-509566-38-00 - Phase 1/2Taking peopleStudy of GVV858 as a single agent or in combination with endocrine therapy in patients with HR+/HER2- breast cancer and other advanced solid tumors
- Where
- Pierre-Bénite
- Age
- 18 years and over
- People
- 55 worldwide
- Run by
- Novartis Pharma AG
See details and how to join2025-521911-38-00 - Phase 1Taking peoplePhase I open-label, multi-center study to evaluate the safety, tolerability, dosimetry, and preliminary activity of [177Lu]Lu-NNS309 in patients with pancreatic, lung, breast and colorectal cancers.
- Where
- Bron, Lyon Cedex 03, Pierre-Bénite, Villejuif
- Age
- 18 years and over
- People
- 76 worldwide
- Run by
- Novartis Pharma AG
See details and how to join2023-510356-23-00 - No phaseTaking peopleEvaluation of Circulating Tumor Cells (CTC) Relevance in Breast Cancer Follow-up Using the ScreenCell Device
- Where
- Neuilly-sur-Seine
- Age
- 18 years and over
- People
- 93
- Run by
- ScreenCell
See details and how to joinNCT06807502 - Phase 3Taking peopleECLECTIC: EstroTEP and Circulating Biomarkers for ER-positive HER2-negative Metastatic Breast Cancer Patients
- Where
- Amiens Cedex 1, Bayonne, Bordeaux, Caen Cedex 5, Clermont Ferrand Cedex1, Dijon, Lille, Marseille, Montpellier Cedex 5, Nice Cedex 2, Nimes Cedex 9, Paris, Rennes Cedex, Rouen Cedex, Saint-Cloud, Strasbourg, Toulouse, Tours, Vandouvre Les Nancy
- Age
- 18 years and over
- People
- 300
- Run by
- Institut Curie
See details and how to joinNCT06195709 · EU 2023-506282-66-00 - Phase 1/2Taking peopleMATRIX-IPC 2022-029 A phase I/II study evaluating Tuvusertib (M1774), an ATR Inhibitor, in combination with fulvestrant in hormone receptors-positive and HER2-negative, advanced breast cancers, resistant to CDK4/6 inhibitor plus aromatase inhibitor-based endocrine treatment and with homologous recombination deficiency, oncogenic driver activation and/or other molecular alterations associated with replication stress (RS)
- Where
- Besançon, Dijon, Lille, Lyon, Marseille, Paris, Pierre-Bénite, Rennes Cedex, St Herblain, Toulouse
- Age
- 18 years and over
- People
- 57
- Run by
- Institut Paoli-Calmettes
See details and how to joinNCT05986071 · EU 2023-507485-10-00 - Phase 2Taking peopleTrastuzumab Deruxtecan in First-Line HER2-Positive Metastatic Breast Cancer With Proactive Toxicity Management
- Where
- Avignon, Bordeaux, Bourg En Bresse, Caen Cedex 5, Dijon, Epagny Metz-tessy, Grenoble Cedex 9, Lille, Lyon, Marseille, Nantes, Nice Cedex 2, Paris, Rennes Cedex, Rouen, Saint-Cloud, Saint-Priest-en-Jarez, Strasbourg, Toulouse Cedex 3, Tours, Villejuif
- Age
- 18 years and over
- People
- 300 worldwide
- Run by
- SOLTI Breast Cancer Research Group
See details and how to joinNCT07371585 · EU 2025-521805-41-00 - Phase 4Taking peopleInfluence des caractéristiques morphologiques sur la pharmacocinétique et la toxicité du trastuzumab-déruxtécan chez des patients ayant un cancer du sein métastatique (TDXdose)
- Where
- Angers, Dijon, Lille, Marseille, Nimes Cedex 9, Paris, Rennes Cedex, Saint-Herblain Cedex, Strasbourg, Toulouse, Vandoeuvre Les Nancy_ Cedex
- Age
- 18 years and over
- People
- 210
- Run by
- Oncopole Claudius Regaud
See details and how to join2025-522656-68-00 - Phase 2Not yet taking people in FranceTucatinib and Trastuzumab in HER3-mutant and HER2-not Amplified Metastatic Breast Cancer
- Where
- Bordeaux, Limoges Cedex 1, Marseille, Nice Cedex 2, Nimes Cedex 9, Rennes Cedex, Saint-Cloud, Toulouse Cedex 9, Vandoeuvre Les Nancy_ Cedex
- Age
- 18 years and over
- People
- 20
- Run by
- Institut Curie
See details and how to joinNCT07193394 · EU 2024-519624-24-00 - No phaseTaking peopleStudy Evaluating DNA Double-strand Breaks (DSBs) REpair Factors (POLQ, Shieldin Complex and 53BP1) Expression as Biomarker of PARP Inhibitor Resistance in Patients With Deleterious Germline Mutation in BRCA 1/2 and HER2-negative, Metastatic or Locally Advanced Breast Cancer.
- Where
- Bordeaux, Caen, Clermont-Ferrand, Dijon, La Roche-sur-Yon, Lille, Limoges, Lyon, Marseille, Montpellier, Nîmes, Paris, Plérin, Poitiers, Rennes, Saint-Etienne, Saint-Herblain, Toulouse, Tours, Vandœuvre-lès-Nancy, Villejuif
- Age
- 18 years and over
- People
- 120
- Run by
- Institut Claudius Regaud
See details and how to joinNCT05378204 - No phaseTaking peopleBreast Cancer Organelle Properties and Protein Expression Atlas in the Three Immunohistochemical Subtypes of Breast Cancers
- Where
- Toulouse
- Age
- 18 years and over
- People
- 1,050
- Run by
- Institut Claudius Regaud
See details and how to joinNCT07233928 - No phaseTaking peopleEfficacy of Personalized Tumorogram-based Therapy in Cancer Established From Patient-derived Organoid (AVATAR)
- Where
- Paris, Saint-Cloud
- Age
- 18 years and over
- People
- 110
- Run by
- Institut Curie
See details and how to joinNCT06459791 - Phase 1/2Taking peoplePhase 1/2 Study to Evaluate TH9619 in the Treatment of Advanced Solid Tumors
- Where
- Lyon, Villejuif
- Age
- 18 years and over
- People
- 43 worldwide
- Run by
- One-carbon Therapeutics AB
See details and how to joinNCT07151040 · EU 2024-519639-40-00 - No phaseTaking peopleAssessement of Potential Interest of [68Ga]Ga-PentixaFor PET/CT in Metastatic Triple Negative Breast Cancer Patients
- Where
- Saint-Herblain
- Age
- 18 years and over
- People
- 12
- Run by
- Institut Cancerologie de l'Ouest
See details and how to joinNCT06962163 - Phase 2Taking peoplePatritumab Deruxtecan (U3-1402) in Unresectable Locally Advanced or Metastatic Breast Cancer
- Where
- Dijon, Limoges, Lyon, Marseille, Montpellier, Nice Cedex 2, Paris, Paris Cedex 20, SAINT HERBLAIN, TOULOUSE, Villejuif
- Age
- 18 years and over
- People
- 139
- Run by
- Gustave Roussy, Cancer Campus, Grand Paris
See details and how to joinNCT04965766 · EU 2023-505923-30-00